MX2010004789A - Sistema de liberacion transdermica para hormonas y esteroides. - Google Patents

Sistema de liberacion transdermica para hormonas y esteroides.

Info

Publication number
MX2010004789A
MX2010004789A MX2010004789A MX2010004789A MX2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A
Authority
MX
Mexico
Prior art keywords
steroids
hormones
release system
transdermal release
penetration enhancer
Prior art date
Application number
MX2010004789A
Other languages
English (en)
Spanish (es)
Inventor
Kerrie Setiawan
Adam Watkinson
Original Assignee
Acrux Dds Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrux Dds Pty Ltd filed Critical Acrux Dds Pty Ltd
Publication of MX2010004789A publication Critical patent/MX2010004789A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010004789A 2007-11-02 2008-10-31 Sistema de liberacion transdermica para hormonas y esteroides. MX2010004789A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98478707P 2007-11-02 2007-11-02
PCT/AU2008/001613 WO2009055859A1 (en) 2007-11-02 2008-10-31 Transdermal delivery system for hormones and steroids

Publications (1)

Publication Number Publication Date
MX2010004789A true MX2010004789A (es) 2010-07-05

Family

ID=40590452

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010004789A MX2010004789A (es) 2007-11-02 2008-10-31 Sistema de liberacion transdermica para hormonas y esteroides.
MX2010004788A MX2010004788A (es) 2007-11-02 2008-10-31 Sistema de liberacion transdermica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010004788A MX2010004788A (es) 2007-11-02 2008-10-31 Sistema de liberacion transdermica.

Country Status (17)

Country Link
US (5) US20100297032A1 (enExample)
EP (2) EP2219603B1 (enExample)
JP (2) JP5737942B2 (enExample)
KR (2) KR20100094495A (enExample)
CN (2) CN101883556B (enExample)
AU (2) AU2008318283B2 (enExample)
BR (2) BRPI0819235A2 (enExample)
CA (2) CA2704116A1 (enExample)
DK (2) DK2219603T3 (enExample)
EA (2) EA019760B1 (enExample)
ES (2) ES2494853T3 (enExample)
MX (2) MX2010004789A (enExample)
NZ (2) NZ585033A (enExample)
PL (2) PL2214643T3 (enExample)
PT (2) PT2214643E (enExample)
WO (2) WO2009055859A1 (enExample)
ZA (1) ZA201003553B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
MX2010004789A (es) * 2007-11-02 2010-07-05 Acrux Dds Pty Ltd Sistema de liberacion transdermica para hormonas y esteroides.
JP5073124B2 (ja) * 2010-12-07 2012-11-14 祐徳薬品工業株式会社 ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
EP2857020A4 (en) * 2012-06-05 2015-10-28 Yutoku Pharmaceutical Ind Co Ltd MIRTAZAPINE TRANSDERMALLY ABSORBABLE SKIN ADHESIVE PREPARATION
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
US20150065426A1 (en) * 2013-08-27 2015-03-05 Professional Compounding Centers Of America Testosterone Booster Transdermal Compositions
MX384159B (es) * 2014-05-05 2025-03-14 Repros Therapeutics Inc Formulaciones y métodos para el suministro vaginal de antiprogestinas.
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
PL3261645T3 (pl) * 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
CN107427474A (zh) 2015-04-13 2017-12-01 株式会社Lg生活健康 含有调节神经递质释放的成分的可溶性微针
WO2016167545A1 (ko) * 2015-04-13 2016-10-20 주식회사 엘지생활건강 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들
JP2018515552A (ja) * 2015-05-18 2018-06-14 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 避妊用組成物ならびに有効性改善および副作用調節方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10449201B2 (en) * 2015-08-17 2019-10-22 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery system comprising clobazam
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2018031576A1 (en) * 2016-08-08 2018-02-15 Baucom Karan Y Hormone delivery system and method
CN110099688A (zh) * 2016-11-17 2019-08-06 赛途公司 骨骼肌肥大诱导物
KR102436756B1 (ko) * 2017-01-31 2022-08-29 신신제약 주식회사 비스테로이드계 소염진통제와 살리실산 유도체를 포함하는 경피흡수 제제
GB2560365B (en) 2017-03-09 2021-10-20 Brightwake Ltd Improvements relating to apparatus negative pressure wound therapy
CN107929268A (zh) * 2017-12-19 2018-04-20 郑州泰丰制药有限公司 一种含质子泵抑制剂药物的透皮贴剂及其制备方法
WO2019140087A1 (en) * 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN108703942B (zh) * 2018-04-23 2021-04-06 中山大学 载有纳米材料包裹保胎药物的微针给药系统及制备方法
EP3817731B1 (en) 2018-07-05 2025-09-03 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
KR102592892B1 (ko) 2021-03-12 2023-10-23 충남대학교산학협력단 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK534178A (da) 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH01308225A (ja) * 1988-06-03 1989-12-12 Nissan Chem Ind Ltd 外用医薬組成物
DE69007886T2 (de) * 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US5276079A (en) * 1991-11-15 1994-01-04 Minnesota Mining And Manufacturing Company Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same
EP0661989B1 (en) * 1992-09-21 1997-08-06 PHARMACIA & UPJOHN COMPANY Sustained-release protein formulations
AU5294393A (en) * 1992-10-06 1994-04-26 Upjohn Company, The Topical pharmaceutical compositions
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
GB9902227D0 (en) * 1999-02-01 1999-03-24 Cipla Limited Pharmaceutical composition for topical administration
ATE252380T1 (de) * 1999-02-05 2003-11-15 Cipla Ltd Topische sprays enthaltend eine filmbildende zusammensetzung
WO2001038329A1 (en) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
WO2003039597A1 (en) * 2001-11-09 2003-05-15 Qlt Inc. Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US7704518B2 (en) * 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US20080027033A1 (en) * 2003-11-19 2008-01-31 Acrux Dds Pty Ltd Method and Composition for Treatment of Cutaneous Lesions
CN1882340A (zh) * 2003-11-19 2006-12-20 艾克若克斯Dds有限公司 用于治疗或预防淀粉样变性病的方法和组合物
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
JP4613622B2 (ja) * 2005-01-20 2011-01-19 住友電気工業株式会社 軟磁性材料および圧粉磁心
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CA2604431A1 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
WO2006124681A2 (en) * 2005-05-18 2006-11-23 The Gi Company, Inc. Oral drug delivery system and methods of use thereof
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
US8435944B2 (en) * 2005-06-03 2013-05-07 Acrux Dds Pty Ltd. Method and composition for transdermal drug delivery
CA2617934A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
CA2624788C (en) * 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
WO2008073684A1 (en) * 2006-12-08 2008-06-19 Lipo Chemicals Inc. Composition for treating aging skin comprising a hydroxycinnamic acid such as p-coumaric acid
MX2010004789A (es) * 2007-11-02 2010-07-05 Acrux Dds Pty Ltd Sistema de liberacion transdermica para hormonas y esteroides.
JP5675175B2 (ja) * 2009-06-23 2015-02-25 大陽日酸株式会社 オゾン供給装置

Also Published As

Publication number Publication date
CN101883556A (zh) 2010-11-10
JP2011502173A (ja) 2011-01-20
US20130317122A1 (en) 2013-11-28
US20100297032A1 (en) 2010-11-25
KR20100094983A (ko) 2010-08-27
ZA201003553B (en) 2011-02-23
CN101883556B (zh) 2013-05-29
CA2704117A1 (en) 2009-05-07
ES2466676T3 (es) 2014-06-10
KR101662186B1 (ko) 2016-10-04
PL2219603T3 (pl) 2014-10-31
HK1144375A1 (en) 2011-02-18
AU2008318284A1 (en) 2009-05-07
EP2219603A1 (en) 2010-08-25
EP2214643A4 (en) 2010-12-01
AU2008318284B2 (en) 2012-03-22
JP5737942B2 (ja) 2015-06-17
EP2214643B1 (en) 2014-04-02
CN101888830A (zh) 2010-11-17
US9078810B2 (en) 2015-07-14
PL2214643T3 (pl) 2014-09-30
DK2214643T3 (da) 2014-05-26
AU2008318283B2 (en) 2012-03-29
CA2704116A1 (en) 2009-05-07
CA2704117C (en) 2015-11-17
MX2010004788A (es) 2010-09-14
PT2214643E (pt) 2014-05-26
EP2219603A4 (en) 2010-11-17
NZ585033A (en) 2011-12-22
CN101888830B (zh) 2013-01-23
WO2009055859A1 (en) 2009-05-07
EP2219603B1 (en) 2014-07-16
KR20100094495A (ko) 2010-08-26
BRPI0819235A2 (pt) 2017-08-22
NZ585034A (en) 2011-08-26
BRPI0819245A2 (pt) 2016-07-19
PT2219603E (pt) 2014-09-02
AU2008318283A1 (en) 2009-05-07
EA201000746A1 (ru) 2010-10-29
DK2219603T3 (da) 2014-09-01
ES2494853T3 (es) 2014-09-16
EA019760B1 (ru) 2014-06-30
EP2214643A1 (en) 2010-08-11
HK1143091A1 (en) 2011-03-18
WO2009055860A1 (en) 2009-05-07
US20100279988A1 (en) 2010-11-04
US20130317462A1 (en) 2013-11-28
JP2011502172A (ja) 2011-01-20
EA201000747A1 (ru) 2010-10-29
US20160022820A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX2010004789A (es) Sistema de liberacion transdermica para hormonas y esteroides.
CY1119829T1 (el) Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου
MX347056B (es) Composiciones farmaceuticas.
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
MX2010008945A (es) Sistema de administracion de drogas con efecto estabilizante.
CY1120492T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
WO2008094834A3 (en) Multi-functional drug carriers
DK2029121T3 (da) Transdermalt terapeutisk system indeholdende partikler af virksom bestanddel og med forøget strøm af virksom bestanddel
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
WO2008124735A3 (en) Multi-functional polyglutamate drug carriers
BR112014031773A2 (pt) entrega de drogas biodegradável para composições hidrofóbicas
AR059843A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
EA200870379A1 (ru) Фармацевтическая композиция с замедленным высвобождением на основе системы высвобождения, включающей кислоторастворимый полимер и ph-зависимый полимер
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
WO2010006143A3 (en) Transdermal estrogen device and delivery
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
FI20075547L (fi) Mainosten toimittaminen mobiilissa mainostamisjärjestelmässä
WO2008089413A3 (en) Urea foam
BRPI0809776A2 (pt) "composição de poliamida, sistema de impermeabilização para uma matriz de poliamida, uso de uma resina novolaca de uma poliolefina, artigo e artigo compósito"
CL2008000617A1 (es) Composicion farmaceutica que comprende a un agente calcilitico adminstrado oralmente, induce liberacion rapida y de corta duracion de la hormona paratiroide en el plasma; y proceso para la preparacion de la composicion farmaceutica.
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
BRPI0810192A2 (pt) Aspartato do ácido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diazaespir o [3,4] oct-6-il)-4-oxo-1,4-diidro- [1,8] naftiridina-3-carboxílico, método para preparação do mesmo e composição farmacêutica antimicrobiana compreendendo o mesmo.

Legal Events

Date Code Title Description
FG Grant or registration